Business
BioSpectrum Asia
Novo Nordisk invests RMB 800 M to expand manufacturing plant in China
Novo Nordisk has signed a Memorandum of Understanding (MoU) with TEDA Administrative Commission, agreeing to invest approximately RMB 800 million in the expansion of quality testing laboratories at its Tianjin manufacturing plant.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
DKSH and Bayer launch strategic partnership across multiple markets in Southeast Asia
DKSH Business Unit Healthcare, a strategic healthcare solutions partner and leading provider of market expansion services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, has announced a partnership with life science company Bayer.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Martin Fischer steps in as President and CEO of Zeiss Greater China
Zeiss Group, an expert in Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets, has announced that Martin Fischer will officially take on the role of President and CEO of Zeiss Greater China, effective from October 1, 2025, reporting directly to Andreas Pecher, President and CEO of the Zeiss Group.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
M42 and GE HealthCare join forces to advance AI-enabled solutions in UAE
M42, a global health leader powered by technology, artificial intelligence (AI) and genomics, will collaborate with GE HealthCare, a global innovator in medical technology, pharmaceutical diagnostics and integrated, cloud-first AI-enabled digital solutions, to enhance diagnostic precision and deliver more personalised patient outcomes, marking a significant step forward in the future of smart healthcare in the UAE. M42 and GE HealthCare will harness their combined strengths in advanced AI-powered solutions and explore collaborative goto-market initiatives to deliver smarter, more connected healthcare in the region, with a focus on improving both clinical and operational efficiency.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
IHH Healthcare catalyses clinical research across global network with initial S$5 M fund
Malaysia headquartered IHH Healthcare, a world-leading integrated healthcare provider, has launched a transformative S$5 million (~Rs 34 crore) Research Grant & Innovation Sandbox programme to accelerate clinical research and innovation across its global network.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
"We plan to enter India, Japan, Thailand, and Vietnam to improve the safety of researchers"
As biotech research laboratories, in both industry and academic settings, engage in increasingly complex projects worldwide, ensuring the safety of personnel, equipment, and the surrounding environment becomes paramount.
5 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
The Future Formula: What's Driving Recruitment Innovation in Pharma
The pharmaceutical recruitment process is becoming more organised, strategic, and data-driven, adapting to changing demands and needs.
5 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
"UK-India Free Trade Agreement helps deepen Genomics Collaboration"
Oxford Nanopore Technologies, a global company with its headquarters in the United Kingdom, has signed Letters of Intent with India's Centre for DNA Fingerprinting and Diagnostics (CDFD), and the National Institute of Biomedical Genomics (NIBMG), to develop two new genomic Centres of Excellence Institutes.
5 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Australia develops new ultrasound imaging device to map drug delivery into brain
A new device combining ultrasound and advanced imaging to provide crucial information for the safe delivery of drugs into the brain has been developed by University of Queensland researchers in Australia.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Hong Kong launches gene- related therapy trials to eradicate chronic hepatitis B infection
Researchers in gastroenterology and hepatology at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have initiated multiple clinical trials exploring pioneering generelated therapy for chronic hepatitis B infection, potentially allowing patients to discontinue long-term medication.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
TVM Capital Healthcare on-boards Dr Su-Lin Chong as Operating Partner in Malaysia
TVM Capital Healthcare, a leading international healthcare private equity firm and operator focused on emerging markets, has announced the appointment of Dr Su-Lin Chong as Operating Partner and Investment Committee member.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Korea-Israel partnership to commercialise injectable treatment for focal fat reduction
365mc, South Korea's leading medical institution specialising in fat reduction treatments, and Israel-based Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 in South Korea.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
India-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Hyphens Pharma introduces acne treatment 'Winlevi' in Singapore and Malaysia
Hyphens Pharma, a subsidiary of Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, has announced the launch of Winlevi (clascoterone) cream 1 per cent in Singapore and Malaysia, marking its first entry into Southeast Asia.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
WHO recommends injectable lenacapavir for HIV prevention
The World Health Organization (WHO) has released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
PHC announces exclusive distribution of MaxCyte EXPERT platform in Japan
The Biomedical Division of Japan-based PHC Corporation (PHCbi), a subsidiary of PHC Holdings Corporation (PHCHD), has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte EXPERT platform in Japan.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
WHO launches bold push to raise health taxes and save millions of lives
The World Health Organization (WHO) has launched a major new initiative urging countries to raise real prices on tobacco, alcohol, and sugary drinks by at least 50 per cent by 2035 through health taxes in a move designed to curb chronic diseases and generate critical public revenue.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
UK launches multi-billion- pound compute roadmap for healthcare and other sectors
Quicker health diagnoses, smarter energy supplies, tackling climate change and improved public service delivery - just some huge potential benefits of the new compute roadmap, launched by Department for Science, Innovation and Technology (DSIT) and UK Research and Innovation (UKRI).
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
"HSA is adopting a forward-looking 5P Strategy to tackle challenges"
Adjunct Professor (Dr) Raymond Chua, who stepped into his role as CEO of Singapore’s Health Sciences Authority (HSA) in December 2024, outlines the agency’s current priorities in positioning Singapore as a regional hub for biotech and medtech innovation.
6 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Japan engineers functional liver organoids with organspecific vasculature
Liver organoids with proper blood vessel networks have been successfully produced, as reported by researchers from Institute of Science Tokyo, Japan and Cincinnati Children’s Hospital Medical Center in the US.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Korea supports international patients through medical sharing programme
The Korea International Medical Association, represented by Chairman Young Tae Kim, has signed a Memorandum of Understanding, with the Korea Health Industry Development Institute, led by President Soon Do Cha, and GS Retail, represented by CEO Seo Hong Heo.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Thermo Fisher introduces new assay to help advance future of precision medicine
US-based Thermo Fisher Scientific has announced that the Oncomine Comprehensive Assay Plus is now available on the Ion Torrent Genexus System helping accelerate precision oncology research.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Emergency vaccine response cuts infectious disease deaths by nearly 60%
Researchers at Burnet Institute, in collaboration with Gavi, the Vaccine Alliance, have provided the world’s first ever look at the historical impact of emergency vaccination efforts on public health and global health security, with a comprehensive study of 210 outbreaks of five infectious diseases- cholera, ebola, measles, meningitis and yellow fever, in 49 lower-income countries between 2000 and 2023.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
JCR Pharma licenses gene therapy platform to AstraZeneca Rare Disease unit for $825 M
Japan's JCR Pharmaceuticals has entered into a license agreement with Alexion, AstraZeneca Rare Disease, for JCR’s new, proprietary JUST-AAV capsids to develop genomic medicines.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
China approves world's first dual GCG/GLP-1 receptor agonist for weight loss
Innovent Biologics, Inc. has announced that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
ASEAN has become an imtportant fulcrum in the global pharmaceutical production supply chain
Asia-based BioDlink, a full-service Contract Development and Manufacturing Organisation (CDMO) specialising in biologics and antibody-drug conjugates (ADCs), has built a strong track record over the past decade, offering integrated solutions from early-stage R&D to commercial manufacturing.
4 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Radiopharmaceutical Blockade: Manufacturing and Access Challenges in Australia
Australia is well positioned to become a global player in radiopharmaceuticals, especially theranostics that combine diagnosis and targeted therapy.
3 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
AN Venture Partners announces one of the largest Japan focused biotech funds to date
AN Venture Partners (ANV), a global biotech venture capital firm, has announced the final close of its first fund, AN Venture Partners I, LP, achieving its target of $200 million (JPY29 billion), one of the largest Japan-focused biotech venture capital funds to date, and also one of the largest first-time biotech venture capital funds raised in the past year.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Country wise analysis of startups with funds raising
Asia-Pacific is home to 9,905 active life sciences startups, as of July 20, 2025, according to Tracxn.
2 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Resurging Funding Catapults APAC BIOTECH STARTUPS
Asia-Pacific's biotech startup scene is on the cusp of a renaissance. After a tough 2024 marked by shrinking venture capital, 2025 is showing revived investor enthusiasm and a rebound in funding- especially for oncology, gene therapy, and Al-driven drug discovery. With 9,905 life sciences startups now active across the region, APAC Countries are leveraging scientific innovation, government support, and new incubators to move beyond service roles and develop world-class therapeutic assets. Let's take a closer look at Asia's startup ecosystem, evolution of investor sentiment over the past few years, and buoying biotech areas.
10 min |